##gff-version 3								
##gvf-version 1.10								
##species https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
NC_045512.2	.	snp	105	105	.	+	.	ID=ID_0;Name=g.G-161T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1135;ao=9;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G-161T;aa_name=;hgvs_nt=NC_045512.2:g.161G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007867132867132868;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	174	174	.	+	.	ID=ID_1;Name=g.G-92T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1144;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G-92T;aa_name=;hgvs_nt=NC_045512.2:g.92G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	224	224	.	+	.	ID=ID_2;Name=g.T-42C;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1127;ao=17;dp=1144;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T-42C;aa_name=;hgvs_nt=NC_045512.2:g.42T>C;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01486013986013986;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	241	241	.	+	.	ID=ID_3;Name=g.C-25T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1144;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C-25T;aa_name=;hgvs_nt=NC_045512.2:g.25C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	376	376	.	+	.	ID=ID_4;Name=E37D;alias=E37D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1001;ao=143;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G111T;aa_name=p.E37D;hgvs_nt=NC_045512.2:g.111G>T;hgvs_aa=YP_009724389.1:p.Glu37Asp;hgvs_alias=YP_009724389.1:Glu37Asp;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.125;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	657	657	.	+	.	ID=ID_5;Name=A131V;alias=A131V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1123;ao=20;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C392T;aa_name=p.A131V;hgvs_nt=NC_045512.2:g.392C>T;hgvs_aa=YP_009724389.1:p.Ala131Val;hgvs_alias=YP_009724389.1:Ala131Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.017497812773403325;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	664	664	.	+	.	ID=ID_6;Name=G133G;alias=G133G;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1137;ao=7;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C399T;aa_name=p.G133G;hgvs_nt=NC_045512.2:g.399C>T;hgvs_aa=YP_009724389.1:p.Gly133Gly;hgvs_alias=YP_009724389.1:Gly133Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006118881118881119;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	829	829	.	+	.	ID=ID_7;Name=N188N;alias=N8N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1087;ao=57;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C564T;aa_name=p.N188N;hgvs_nt=NC_045512.2:g.564C>T;hgvs_aa=YP_009724389.1:p.Asn188Asn;hgvs_alias=YP_009724389.1:Asn8Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.049825174825174824;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1059	1059	.	+	.	ID=ID_8;Name=T265I;alias=T85I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=0;ao=1144;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C794T;aa_name=p.T265I;hgvs_nt=NC_045512.2:g.794C>T;hgvs_aa=YP_009724389.1:p.Thr265Ile;hgvs_alias=YP_009724389.1:Thr85Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1348	1348	.	+	.	ID=ID_9;Name=P361P;alias=P181P;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1097;ao=46;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1083T;aa_name=p.P361P;hgvs_nt=NC_045512.2:g.1083C>T;hgvs_aa=YP_009724389.1:p.Pro361Pro;hgvs_alias=YP_009724389.1:Pro181Pro;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04024496937882765;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1463	1463	.	+	.	ID=ID_10;Name=G400C;alias=G220C;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1136;ao=7;dp=1143;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1198T;aa_name=p.G400C;hgvs_nt=NC_045512.2:g.1198G>T;hgvs_aa=YP_009724389.1:p.Gly400Cys;hgvs_alias=YP_009724389.1:Gly220Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006124234470691163;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1931	1931	.	+	.	ID=ID_11;Name=Q556K;alias=Q376K;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1114;ao=29;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=A;nt_name=g.C1666A;aa_name=p.Q556K;hgvs_nt=NC_045512.2:g.1666C>A;hgvs_aa=YP_009724389.1:p.Gln556Lys;hgvs_alias=YP_009724389.1:Gln376Lys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02537182852143482;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2110	2110	.	+	.	ID=ID_12;Name=N615N;alias=N435N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1133;ao=10;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1845T;aa_name=p.N615N;hgvs_nt=NC_045512.2:g.1845C>T;hgvs_aa=YP_009724389.1:p.Asn615Asn;hgvs_alias=YP_009724389.1:Asn435Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008748906386701663;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2377	2377	.	+	.	ID=ID_13;Name=N704N;alias=N524N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1128;ao=16;dp=1144;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T2112C;aa_name=p.N704N;hgvs_nt=NC_045512.2:g.2112T>C;hgvs_aa=YP_009724389.1:p.Asn704Asn;hgvs_alias=YP_009724389.1:Asn524Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013986013986013986;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2445	2445	.	+	.	ID=ID_14;Name=T727I;alias=T547I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1096;ao=48;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2180T;aa_name=p.T727I;hgvs_nt=NC_045512.2:g.2180C>T;hgvs_aa=YP_009724389.1:p.Thr727Ile;hgvs_alias=YP_009724389.1:Thr547Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04195804195804196;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2448	2448	.	+	.	ID=ID_15;Name=G728D;alias=G548D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1137;ao=7;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G2183A;aa_name=p.G728D;hgvs_nt=NC_045512.2:g.2183G>A;hgvs_aa=YP_009724389.1:p.Gly728Asp;hgvs_alias=YP_009724389.1:Gly548Asp;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006118881118881119;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2632	2632	.	+	.	ID=ID_16;Name=M789I;alias=M609I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1138;ao=6;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G2367T;aa_name=p.M789I;hgvs_nt=NC_045512.2:g.2367G>T;hgvs_aa=YP_009724389.1:p.Met789Ile;hgvs_alias=YP_009724389.1:Met609Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005244755244755245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2692	2692	.	+	.	ID=ID_17;Name=T809T;alias=T629T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=162;ao=982;dp=1144;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A2427T;aa_name=p.T809T;hgvs_nt=NC_045512.2:g.2427A>T;hgvs_aa=YP_009724389.1:p.Thr809Thr;hgvs_alias=YP_009724389.1:Thr629Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8583916083916084;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2710	2710	.	+	.	ID=ID_18;Name=L815L;alias=L635L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1134;ao=10;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2445T;aa_name=p.L815L;hgvs_nt=NC_045512.2:g.2445C>T;hgvs_aa=YP_009724389.1:p.Leu815Leu;hgvs_alias=YP_009724389.1:Leu635Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008741258741258742;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2734	2734	.	+	.	ID=ID_19;Name=V823V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1129;ao=15;dp=1144;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T2469C;aa_name=p.V823V;hgvs_nt=NC_045512.2:g.2469T>C;hgvs_aa=YP_009724389.1:p.Val823Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013111888111888112;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2830	2830	.	+	.	ID=ID_20;Name=E855D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1134;ao=10;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G2565T;aa_name=p.E855D;hgvs_nt=NC_045512.2:g.2565G>T;hgvs_aa=YP_009724389.1:p.Glu855Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008741258741258742;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2939	2939	.	+	.	ID=ID_21;Name=P892S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1133;ao=11;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2674T;aa_name=p.P892S;hgvs_nt=NC_045512.2:g.2674C>T;hgvs_aa=YP_009724389.1:p.Pro892Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009615384615384616;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2946	2946	.	+	.	ID=ID_22;Name=G894D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1136;ao=7;dp=1143;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G2681A;aa_name=p.G894D;hgvs_nt=NC_045512.2:g.2681G>A;hgvs_aa=YP_009724389.1:p.Gly894Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006124234470691163;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3037	3037	.	+	.	ID=ID_23;Name=F924F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=1144;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2772T;aa_name=p.F924F;hgvs_nt=NC_045512.2:g.2772C>T;hgvs_aa=YP_009724389.1:p.Phe924Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3330	3330	.	+	.	ID=ID_24;Name=T1022I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1096;ao=48;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C3065T;aa_name=p.T1022I;hgvs_nt=NC_045512.2:g.3065C>T;hgvs_aa=YP_009724389.1:p.Thr1022Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04195804195804196;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3728	3728	.	+	.	ID=ID_25;Name=G1155C;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1093;ao=51;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G3463T;aa_name=p.G1155C;hgvs_nt=NC_045512.2:g.3463G>T;hgvs_aa=YP_009724389.1:p.Gly1155Cys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044580419580419584;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3774	3774	.	+	.	ID=ID_26;Name=R1170L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1129;ao=15;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G3509T;aa_name=p.R1170L;hgvs_nt=NC_045512.2:g.3509G>T;hgvs_aa=YP_009724389.1:p.Arg1170Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013111888111888112;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3871	3871	.	+	.	ID=ID_27;Name=K1202N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1118;ao=26;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G3606T;aa_name=p.K1202N;hgvs_nt=NC_045512.2:g.3606G>T;hgvs_aa=YP_009724389.1:p.Lys1202Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022727272727272728;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3924	3924	.	+	.	ID=ID_28;Name=P1220L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1087;ao=57;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C3659T;aa_name=p.P1220L;hgvs_nt=NC_045512.2:g.3659C>T;hgvs_aa=YP_009724389.1:p.Pro1220Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.049825174825174824;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3966	3966	.	+	.	ID=ID_29;Name=A1234V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1134;ao=10;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C3701T;aa_name=p.A1234V;hgvs_nt=NC_045512.2:g.3701C>T;hgvs_aa=YP_009724389.1:p.Ala1234Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008741258741258742;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4213	4213	.	+	.	ID=ID_30;Name=A1316A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1062;ao=82;dp=1144;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T3948C;aa_name=p.A1316A;hgvs_nt=NC_045512.2:g.3948T>C;hgvs_aa=YP_009724389.1:p.Ala1316Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07167832167832168;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4234	4234	.	+	.	ID=ID_31;Name=D1323D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1127;ao=17;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C3969T;aa_name=p.D1323D;hgvs_nt=NC_045512.2:g.3969C>T;hgvs_aa=YP_009724389.1:p.Asp1323Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01486013986013986;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4276	4276	.	+	.	ID=ID_32;Name=Y1337Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1135;ao=9;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C4011T;aa_name=p.Y1337Y;hgvs_nt=NC_045512.2:g.4011C>T;hgvs_aa=YP_009724389.1:p.Tyr1337Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007867132867132868;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4897	4897	.	+	.	ID=ID_33;Name=F1544F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1099;ao=45;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C4632T;aa_name=p.F1544F;hgvs_nt=NC_045512.2:g.4632C>T;hgvs_aa=YP_009724389.1:p.Phe1544Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.039335664335664336;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4999	4999	.	+	.	ID=ID_34;Name=N1578N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1092;ao=46;dp=1138;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C4734T;aa_name=p.N1578N;hgvs_nt=NC_045512.2:g.4734C>T;hgvs_aa=YP_009724389.1:p.Asn1578Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.040421792618629174;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5050	5050	.	+	.	ID=ID_35;Name=G1595G;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1131;ao=7;dp=1138;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T4785C;aa_name=p.G1595G;hgvs_nt=NC_045512.2:g.4785T>C;hgvs_aa=YP_009724389.1:p.Gly1595Gly;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006151142355008787;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5100	5100	.	+	.	ID=ID_36;Name=S1612L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=849;ao=288;dp=1137;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C4835T;aa_name=p.S1612L;hgvs_nt=NC_045512.2:g.4835C>T;hgvs_aa=YP_009724389.1:p.Ser1612Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.2532981530343008;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	complex	5226	5226	.	+	.	ID=ID_37;Name=K1655N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=7;dp=1138;sample_size=1180;Reference_seq=AAAAG;Variant_seq=GAAAT;nt_name=g.G4965T;aa_name=p.K1655N;hgvs_nt=NC_045512.2:g.4965G>T;hgvs_aa=YP_009724389.1:p.Lys1655Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006151142355008787;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5226	5226	.	+	.	ID=ID_38;Name=KK1654RN;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=1131;dp=1138;sample_size=1180;Reference_seq=AAAAG;Variant_seq=AAAAT;nt_name=g.AAAAG4961_4965GAAAT;aa_name=p.KK1654RN;hgvs_nt=n/a;hgvs_aa=YP_009724389.1:p.LysLys1654ArgAsn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9938488576449912;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5284	5284	.	+	.	ID=ID_39;Name=N1673N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1121;ao=12;dp=1133;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C5019T;aa_name=p.N1673N;hgvs_nt=NC_045512.2:g.5019C>T;hgvs_aa=YP_009724389.1:p.Asn1673Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01059135039717564;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5512	5512	.	+	.	ID=ID_40;Name=N1749N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1094;ao=46;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C5247T;aa_name=p.N1749N;hgvs_nt=NC_045512.2:g.5247C>T;hgvs_aa=YP_009724389.1:p.Asn1749Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04035087719298246;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5526	5526	.	+	.	ID=ID_41;Name=T1754I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1129;ao=10;dp=1139;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C5261T;aa_name=p.T1754I;hgvs_nt=NC_045512.2:g.5261C>T;hgvs_aa=YP_009724389.1:p.Thr1754Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00877963125548727;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5553	5553	.	+	.	ID=ID_42;Name=K1763R;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1129;ao=11;dp=1140;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A5288G;aa_name=p.K1763R;hgvs_nt=NC_045512.2:g.5288A>G;hgvs_aa=YP_009724389.1:p.Lys1763Arg;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009649122807017544;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6354	6354	.	+	.	ID=ID_43;Name=S2030L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1095;ao=48;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C6089T;aa_name=p.S2030L;hgvs_nt=NC_045512.2:g.6089C>T;hgvs_aa=YP_009724389.1:p.Ser2030Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04199475065616798;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6471	6471	.	+	.	ID=ID_44;Name=T2069I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1098;ao=45;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C6206T;aa_name=p.T2069I;hgvs_nt=NC_045512.2:g.6206C>T;hgvs_aa=YP_009724389.1:p.Thr2069Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03937007874015748;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6936	6936	.	+	.	ID=ID_45;Name=S2224F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1114;ao=29;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C6671T;aa_name=p.S2224F;hgvs_nt=NC_045512.2:g.6671C>T;hgvs_aa=YP_009724389.1:p.Ser2224Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02537182852143482;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6968	6968	.	+	.	ID=ID_46;Name=L2235L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1115;ao=29;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C6703T;aa_name=p.L2235L;hgvs_nt=NC_045512.2:g.6703C>T;hgvs_aa=YP_009724389.1:p.Leu2235Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025349650349650348;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7000	7000	.	+	.	ID=ID_47;Name=Y2245Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1096;ao=48;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C6735T;aa_name=p.Y2245Y;hgvs_nt=NC_045512.2:g.6735C>T;hgvs_aa=YP_009724389.1:p.Tyr2245Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04195804195804196;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7113	7113	.	+	.	ID=ID_48;Name=T2283I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1102;ao=37;dp=1139;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C6848T;aa_name=p.T2283I;hgvs_nt=NC_045512.2:g.6848C>T;hgvs_aa=YP_009724389.1:p.Thr2283Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0324846356453029;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7267	7267	.	+	.	ID=ID_49;Name=F2334F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1092;ao=48;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C7002T;aa_name=p.F2334F;hgvs_nt=NC_045512.2:g.7002C>T;hgvs_aa=YP_009724389.1:p.Phe2334Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.042105263157894736;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7564	7564	.	+	.	ID=ID_50;Name=S2433S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1134;ao=10;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C7299T;aa_name=p.S2433S;hgvs_nt=NC_045512.2:g.7299C>T;hgvs_aa=YP_009724389.1:p.Ser2433Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008741258741258742;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8017	8017	.	+	.	ID=ID_51;Name=A2584A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1115;ao=29;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G7752T;aa_name=p.A2584A;hgvs_nt=NC_045512.2:g.7752G>T;hgvs_aa=YP_009724389.1:p.Ala2584Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025349650349650348;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8578	8578	.	+	.	ID=ID_52;Name=K2771N;alias=K8N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=1126;ao=17;dp=1143;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G8313T;aa_name=p.K2771N;hgvs_nt=NC_045512.2:g.8313G>T;hgvs_aa=YP_009724389.1:p.Lys2771Asn;hgvs_alias=YP_009724389.1:Lys8Asn;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014873140857392825;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8964	8964	.	+	.	ID=ID_53;Name=S2900L;alias=S137L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=1138;ao=6;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C8699T;aa_name=p.S2900L;hgvs_nt=NC_045512.2:g.8699C>T;hgvs_aa=YP_009724389.1:p.Ser2900Leu;hgvs_alias=YP_009724389.1:Ser137Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005244755244755245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9073	9073	.	+	.	ID=ID_54;Name=T2936T;alias=T173T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=1103;ao=40;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C8808T;aa_name=p.T2936T;hgvs_nt=NC_045512.2:g.8808C>T;hgvs_aa=YP_009724389.1:p.Thr2936Thr;hgvs_alias=YP_009724389.1:Thr173Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03499562554680665;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9167	9167	.	+	.	ID=ID_55;Name=Y2968H;alias=Y205H;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=1128;ao=16;dp=1144;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T8902C;aa_name=p.Y2968H;hgvs_nt=NC_045512.2:g.8902T>C;hgvs_aa=YP_009724389.1:p.Tyr2968His;hgvs_alias=YP_009724389.1:Tyr205His;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013986013986013986;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9246	9246	.	+	.	ID=ID_56;Name=A2994V;alias=A231V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=1109;ao=30;dp=1139;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C8981T;aa_name=p.A2994V;hgvs_nt=NC_045512.2:g.8981C>T;hgvs_aa=YP_009724389.1:p.Ala2994Val;hgvs_alias=YP_009724389.1:Ala231Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02633889376646181;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9511	9511	.	+	.	ID=ID_57;Name=T3082T;alias=T319T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=1135;ao=9;dp=1144;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T9246C;aa_name=p.T3082T;hgvs_nt=NC_045512.2:g.9246T>C;hgvs_aa=YP_009724389.1:p.Thr3082Thr;hgvs_alias=YP_009724389.1:Thr319Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007867132867132868;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9689	9689	.	+	.	ID=ID_58;Name=I3142V;alias=I379V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=1127;ao=17;dp=1144;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A9424G;aa_name=p.I3142V;hgvs_nt=NC_045512.2:g.9424A>G;hgvs_aa=YP_009724389.1:p.Ile3142Val;hgvs_alias=YP_009724389.1:Ile379Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01486013986013986;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9803	9803	.	+	.	ID=ID_59;Name=L3180L;alias=L417L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=1134;ao=10;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C9538T;aa_name=p.L3180L;hgvs_nt=NC_045512.2:g.9538C>T;hgvs_aa=YP_009724389.1:p.Leu3180Leu;hgvs_alias=YP_009724389.1:Leu417Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008741258741258742;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	complex	10323	10323	.	+	.	ID=ID_60;Name=K3353R;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=0;ao=37;dp=1144;sample_size=1180;Reference_seq=AG;Variant_seq=GA;nt_name=g.A10058G;aa_name=p.K3353R;hgvs_nt=NC_045512.2:g.10058A>G;hgvs_aa=YP_009724389.1:p.Lys3353Arg;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.032342657342657344;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10323	10323	.	+	.	ID=ID_60;Name=K3353R;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=0;ao=1107;dp=1144;sample_size=1180;Reference_seq=AG;Variant_seq=GG;nt_name=g.AG10058_10059GA;aa_name=p.K3353R;hgvs_nt=n/a;hgvs_aa=YP_009724389.1:p.Lys3353Arg;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9676573426573427;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10369	10369	.	+	.	ID=ID_61;Name=R3368R;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=1104;ao=40;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C10104T;aa_name=p.R3368R;hgvs_nt=NC_045512.2:g.10104C>T;hgvs_aa=YP_009724389.1:p.Arg3368Arg;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03496503496503497;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10833	10833	.	+	.	ID=ID_62;Name=A3523V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=1112;ao=7;dp=1119;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C10568T;aa_name=p.A3523V;hgvs_nt=NC_045512.2:g.10568C>T;hgvs_aa=YP_009724389.1:p.Ala3523Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006255585344057194;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11083	11083	.	+	.	ID=ID_63;Name=L3606F;alias=L37F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1109;ao=31;dp=1140;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G10818T;aa_name=p.L3606F;hgvs_nt=NC_045512.2:g.10818G>T;hgvs_aa=YP_009724389.1:p.Leu3606Phe;hgvs_alias=YP_009724389.1:Leu37Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.027192982456140352;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11266	11266	.	+	.	ID=ID_64;Name=L3667L;alias=L98L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1044;ao=99;dp=1143;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G11001A;aa_name=p.L3667L;hgvs_nt=NC_045512.2:g.11001G>A;hgvs_aa=YP_009724389.1:p.Leu3667Leu;hgvs_alias=YP_009724389.1:Leu98Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.08661417322834646;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_65;Name=S3675del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=1143;dp=1143;sample_size=1180;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=3676del,F3677del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_65;Name=3676del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=1143;dp=1143;sample_size=1180;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=S3675del,F3677del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_65;Name=F3677del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=1143;dp=1143;sample_size=1180;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=S3675del,3676del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11522	11522	.	+	.	ID=ID_66;Name=F3753V;alias=F184V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=999;ao=143;dp=1142;sample_size=1180;Reference_seq=T;Variant_seq=G;nt_name=g.T11257G;aa_name=p.F3753V;hgvs_nt=NC_045512.2:g.11257T>G;hgvs_aa=YP_009724389.1:p.Phe3753Val;hgvs_alias=YP_009724389.1:Phe184Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.12521891418563924;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11750	11750	.	+	.	ID=ID_67;Name=L3829F;alias=L260F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1131;ao=10;dp=1141;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C11485T;aa_name=p.L3829F;hgvs_nt=NC_045512.2:g.11485C>T;hgvs_aa=YP_009724389.1:p.Leu3829Phe;hgvs_alias=YP_009724389.1:Leu260Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008764241893076249;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11812	11812	.	+	.	ID=ID_68;Name=G3849G;alias=G280G;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1062;ao=82;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=A;nt_name=g.C11547A;aa_name=p.G3849G;hgvs_nt=NC_045512.2:g.11547C>A;hgvs_aa=YP_009724389.1:p.Gly3849Gly;hgvs_alias=YP_009724389.1:Gly280Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07167832167832168;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11940	11940	.	+	.	ID=ID_69;Name=V3892A;alias=V33A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3860..3942;ro=1137;ao=7;dp=1144;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T11675C;aa_name=p.V3892A;hgvs_nt=NC_045512.2:g.11675T>C;hgvs_aa=YP_009724389.1:p.Val3892Ala;hgvs_alias=YP_009724389.1:Val33Ala;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006118881118881119;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12008	12008	.	+	.	ID=ID_70;Name=L3915F;alias=L56F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3860..3942;ro=1128;ao=16;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C11743T;aa_name=p.L3915F;hgvs_nt=NC_045512.2:g.11743C>T;hgvs_aa=YP_009724389.1:p.Leu3915Phe;hgvs_alias=YP_009724389.1:Leu56Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013986013986013986;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12134	12134	.	+	.	ID=ID_71;Name=F3957L;alias=F15L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=1087;ao=57;dp=1144;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T11869C;aa_name=p.F3957L;hgvs_nt=NC_045512.2:g.11869T>C;hgvs_aa=YP_009724389.1:p.Phe3957Leu;hgvs_alias=YP_009724389.1:Phe15Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.049825174825174824;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12439	12439	.	+	.	ID=ID_72;Name=P4058P;alias=P116P;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=1109;ao=34;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C12174T;aa_name=p.P4058P;hgvs_nt=NC_045512.2:g.12174C>T;hgvs_aa=YP_009724389.1:p.Pro4058Pro;hgvs_alias=YP_009724389.1:Pro116Pro;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02974628171478565;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13944	13944	.	+	.	ID=ID_73;Name=N4560N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1133;ao=11;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C13680T;aa_name=p.N4560N;hgvs_nt=NC_045512.2:g.13680C>T;hgvs_aa=YP_009724389.1:p.Asn4560Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009615384615384616;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14408	14408	.	+	.	ID=ID_74;Name=P4715H;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=568;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=A;nt_name=g.C14144A;aa_name=p.P4715H;hgvs_nt=NC_045512.2:g.14144C>A;hgvs_aa=YP_009724389.1:p.Pro4715His;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4965034965034965;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14408	14408	.	+	.	ID=ID_75;Name=P4715L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=575;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C14144T;aa_name=p.P4715L;hgvs_nt=NC_045512.2:g.14144C>T;hgvs_aa=YP_009724389.1:p.Pro4715Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5026223776223776;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15925	15925	.	+	.	ID=ID_76;Name=L5221F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1060;ao=82;dp=1142;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C15661T;aa_name=p.L5221F;hgvs_nt=NC_045512.2:g.15661C>T;hgvs_aa=YP_009724389.1:p.Leu5221Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07180385288966724;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16181	16181	.	+	.	ID=ID_77;Name=R5306K;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1119;ao=22;dp=1141;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G15917A;aa_name=p.R5306K;hgvs_nt=NC_045512.2:g.15917G>A;hgvs_aa=YP_009724389.1:p.Arg5306Lys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.019281332164767746;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16726	16726	.	+	.	ID=ID_78;Name=H5488Y;alias=H164Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1126;ao=18;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C16462T;aa_name=p.H5488Y;hgvs_nt=NC_045512.2:g.16462C>T;hgvs_aa=YP_009724389.1:p.His5488Tyr;hgvs_alias=YP_009724389.1:His164Tyr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015734265734265736;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17658	17658	.	+	.	ID=ID_79;Name=M5798I;alias=M474I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1128;ao=16;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G17394T;aa_name=p.M5798I;hgvs_nt=NC_045512.2:g.17394G>T;hgvs_aa=YP_009724389.1:p.Met5798Ile;hgvs_alias=YP_009724389.1:Met474Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013986013986013986;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17970	17970	.	+	.	ID=ID_80;Name=D5902D;alias=D578D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1061;ao=82;dp=1143;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T17706C;aa_name=p.D5902D;hgvs_nt=NC_045512.2:g.17706T>C;hgvs_aa=YP_009724389.1:p.Asp5902Asp;hgvs_alias=YP_009724389.1:Asp578Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07174103237095363;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17999	17999	.	+	.	ID=ID_81;Name=T5912I;alias=T588I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1093;ao=51;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C17735T;aa_name=p.T5912I;hgvs_nt=NC_045512.2:g.17735C>T;hgvs_aa=YP_009724389.1:p.Thr5912Ile;hgvs_alias=YP_009724389.1:Thr588Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044580419580419584;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18525	18525	.	+	.	ID=ID_82;Name=V6087V;alias=V162V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1133;ao=10;dp=1143;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G18261T;aa_name=p.V6087V;hgvs_nt=NC_045512.2:g.18261G>T;hgvs_aa=YP_009724389.1:p.Val6087Val;hgvs_alias=YP_009724389.1:Val162Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008748906386701663;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19019	19019	.	+	.	ID=ID_83;Name=P6252Q;alias=P327Q;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1137;ao=7;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=A;nt_name=g.C18755A;aa_name=p.P6252Q;hgvs_nt=NC_045512.2:g.18755C>A;hgvs_aa=YP_009724389.1:p.Pro6252Gln;hgvs_alias=YP_009724389.1:Pro327Gln;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006118881118881119;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19113	19113	.	+	.	ID=ID_84;Name=D6283D;alias=D358D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1000;ao=144;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C18849T;aa_name=p.D6283D;hgvs_nt=NC_045512.2:g.18849C>T;hgvs_aa=YP_009724389.1:p.Asp6283Asp;hgvs_alias=YP_009724389.1:Asp358Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1258741258741259;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19524	19524	.	+	.	ID=ID_85;Name=L6420L;alias=L495L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=874;ao=194;dp=1068;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C19260T;aa_name=p.L6420L;hgvs_nt=NC_045512.2:g.19260C>T;hgvs_aa=YP_009724389.1:p.Leu6420Leu;hgvs_alias=YP_009724389.1:Leu495Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.18164794007490637;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19656	19656	.	+	.	ID=ID_86;Name=K6464N;alias=K12N;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=1102;ao=40;dp=1142;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G19392T;aa_name=p.K6464N;hgvs_nt=NC_045512.2:g.19392G>T;hgvs_aa=YP_009724389.1:p.Lys6464Asn;hgvs_alias=YP_009724389.1:Lys12Asn;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03502626970227671;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20102	20102	.	+	.	ID=ID_87;Name=S6613I;alias=S161I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=966;ao=143;dp=1109;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G19838T;aa_name=p.S6613I;hgvs_nt=NC_045512.2:g.19838G>T;hgvs_aa=YP_009724389.1:p.Ser6613Ile;hgvs_alias=YP_009724389.1:Ser161Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.12894499549143373;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20233	20233	.	+	.	ID=ID_88;Name=P6657S;alias=P205S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=1102;ao=40;dp=1142;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C19969T;aa_name=p.P6657S;hgvs_nt=NC_045512.2:g.19969C>T;hgvs_aa=YP_009724389.1:p.Pro6657Ser;hgvs_alias=YP_009724389.1:Pro205Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03502626970227671;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20628	20628	.	+	.	ID=ID_89;Name=G6788G;alias=G336G;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=1134;ao=10;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C20364T;aa_name=p.G6788G;hgvs_nt=NC_045512.2:g.20364C>T;hgvs_aa=YP_009724389.1:p.Gly6788Gly;hgvs_alias=YP_009724389.1:Gly336Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008741258741258742;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21255	21255	.	+	.	ID=ID_90;Name=A6997A;alias=A199A;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=1110;ao=14;dp=1124;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G20991T;aa_name=p.A6997A;hgvs_nt=NC_045512.2:g.20991G>T;hgvs_aa=YP_009724389.1:p.Ala6997Ala;hgvs_alias=YP_009724389.1:Ala199Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012455516014234875;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21367	21367	.	+	.	ID=ID_91;Name=I7035F;alias=I237F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=1114;ao=7;dp=1121;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A21103T;aa_name=p.I7035F;hgvs_nt=NC_045512.2:g.21103A>T;hgvs_aa=YP_009724389.1:p.Ile7035Phe;hgvs_alias=YP_009724389.1:Ile237Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006244424620874219;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21510	21510	.	+	.	ID=ID_92;Name=E7082E;alias=E284E;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=1080;ao=57;dp=1137;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A21246G;aa_name=p.E7082E;hgvs_nt=NC_045512.2:g.21246A>G;hgvs_aa=YP_009724389.1:p.Glu7082Glu;hgvs_alias=YP_009724389.1:Glu284Glu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05013192612137203;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_93;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1130;ao=7;dp=1137;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006156552330694811;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_93;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1130;ao=7;dp=1137;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006156552330694811;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_93;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1130;ao=7;dp=1137;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006156552330694811;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	"ID=ID_94;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=485;ao=653;dp=1138;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5738137082601055;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_94;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=485;ao=653;dp=1138;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5738137082601055;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Ablates neutralization by N-terminal-domain-targeting mAbs 4-19. Impairs neutralization by N-terminal-domain-targeting mAbs 4A8 and 2-17.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_95;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=485;ao=653;dp=1138;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5738137082601055;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_94;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=485;ao=653;dp=1138;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5738137082601055;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggetsing that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	"ID=ID_94;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=485;ao=653;dp=1138;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5738137082601055;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_94;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=485;ao=653;dp=1138;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5738137082601055;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_95;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=485;ao=653;dp=1138;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5738137082601055;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_95;Name=L18F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=485;ao=653;dp=1138;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18F;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724390.1:p.Leu18Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5738137082601055;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21641	21641	.	+	.	ID=ID_96;Name=A27S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1056;ao=82;dp=1138;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G79T;aa_name=p.A27S;hgvs_nt=NC_045512.2:g.79G>T;hgvs_aa=YP_009724390.1:p.Ala27Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07205623901581722;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21678	21678	.	+	.	ID=ID_97;Name=P39L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1087;ao=51;dp=1138;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C116T;aa_name=p.P39L;hgvs_nt=NC_045512.2:g.116C>T;hgvs_aa=YP_009724390.1:p.Pro39Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04481546572934974;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21711	21711	.	+	.	ID=ID_98;Name=S50L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1101;ao=7;dp=1108;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C149T;aa_name=p.S50L;hgvs_nt=NC_045512.2:g.149C>T;hgvs_aa=YP_009724390.1:p.Ser50Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00631768953068592;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_99;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=Munster et al. (2021);comb_mutation=D215G,K417N,A701V,N501Y,E484K;function_description=Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_100;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D215G,K417N,E484K,N501Y,A701V,D614G;function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_101;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Abolishes neutralizing activity of N-terminal-domain-directed mAb 4-19.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_102;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination showed no change relative to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_101;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_100;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D215G,K417N,E484K,N501Y,A701V,D614G;function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	"ID=ID_101;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_101;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_102;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_100;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D215G,K417N,E484K,N501Y,A701V,D614G;function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_99;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=D215G,K417N,E484K,N501Y,A701V;function_description=Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_101;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=CD8 plus T cell response;source=https://www.medrxiv.org/content/10.1101/2021.02.11.21251585v1;citation=Redd et al. (2021);comb_mutation=;function_description=One individual of 30 in the study, with HLA supertype HLA*A24:02, had a linear epitope that overlaps this variant of concern.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_101;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated that there is no free energy change (ddG) for this variant (i.e. same stability as wild type);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_99;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=Yinda et al. (2021);comb_mutation=D215G,K417N,A701V,N501Y,E484K;function_description=Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_99;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=Staub et al. (2021);comb_mutation=D215G,K417N,A701V,N501Y,E484K;function_description=4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21801	21801	.	+	.	ID=ID_102;Name=D80A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1108;dp=1108;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A239C;aa_name=p.D80A;hgvs_nt=NC_045512.2:g.239A>C;hgvs_aa=YP_009724390.1:p.Asp80Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.64x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.35x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22021	22021	.	+	.	ID=ID_103;Name=M153I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1099;ao=42;dp=1141;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G459T;aa_name=p.M153I;hgvs_nt=NC_045512.2:g.459G>T;hgvs_aa=YP_009724390.1:p.Met153Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03680981595092025;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_99;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=Munster et al. (2021);comb_mutation=D80A,K417N,A701V,N501Y,E484K;function_description=Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_104;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_100;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,K417N,E484K,N501Y,A701V,D614G;function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_105;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.19x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_104;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_100;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,K417N,E484K,N501Y,A701V,D614G;function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	"ID=ID_104;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_104;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_105;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_100;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,K417N,E484K,N501Y,A701V,D614G;function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_99;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=D80A,K417N,E484K,N501Y,A701V;function_description=Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_104;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.98 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_99;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=Yinda et al. (2021);comb_mutation=D80A,K417N,A701V,N501Y,E484K;function_description=Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_99;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=Staub et al. (2021);comb_mutation=D80A,K417N,A701V,N501Y,E484K;function_description=4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22206	22206	.	+	.	ID=ID_105;Name=D215G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A644G;aa_name=p.D215G;hgvs_nt=NC_045512.2:g.644A>G;hgvs_aa=YP_009724390.1:p.Asp215Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.79x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22227	22227	.	+	.	"ID=ID_106;Name=A222V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1137;ao=6;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C665T;aa_name=p.A222V;hgvs_nt=NC_045512.2:g.665C>T;hgvs_aa=YP_009724390.1:p.Ala222Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005249343832020997;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Not associated with significant reduction of EC50 (recognition) in any antigenic supersite ""i"" monoclonal antibodies.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22227	22227	.	+	.	ID=ID_107;Name=A222V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1137;ao=6;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C665T;aa_name=p.A222V;hgvs_nt=NC_045512.2:g.665C>T;hgvs_aa=YP_009724390.1:p.Ala222Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005249343832020997;function_category=humoral response durability;source=https://dx.doi.org/10.3390%2Fv13040661;citation=Brehm et al. (2021);comb_mutation=D614G;function_description=27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3), i.e. with a  9 month interval. Both cases were mild. No significant differences in the neutralizing capacity of the two linages were observed in 4 sera taken (1 pre-reinfection,  three post-reinfection). Neutralizing antibody titres (IC50) before and immediately after re-infection were <300 against  both strains, and jumped >7x upon re-infection. Viral titres were also higher in the second case. Second case also includes N:p.A220V;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22227	22227	.	+	.	ID=ID_107;Name=A222V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1137;ao=6;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C665T;aa_name=p.A222V;hgvs_nt=NC_045512.2:g.665C>T;hgvs_aa=YP_009724390.1:p.Ala222Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005249343832020997;function_category=reinfection;source=https://dx.doi.org/10.3390%2Fv13040661;citation=Brehm et al. (2021);comb_mutation=D614G;function_description=27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3). Both cases were mild. Second case also includes N:p.A220V;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	22280	22280	.	+	.	ID=ID_108;Name=L242_L244del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=929;dp=935;sample_size=1180;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=g.725_733delTTGCTTTAC;aa_name=p.L242_L244del;hgvs_nt=NC_045512.2:g.725_733del;hgvs_aa=YP_009724390.1:p.Leu242_Leu244del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9935828877005347;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22420	22420	.	+	.	ID=ID_109;Name=T286T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=372;ao=2;dp=374;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A858G;aa_name=p.T286T;hgvs_nt=NC_045512.2:g.858A>G;hgvs_aa=YP_009724390.1:p.Thr286Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053475935828877;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22525	22525	.	+	.	ID=ID_110;Name=Q321Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=357;ao=14;dp=371;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A963G;aa_name=p.Q321Q;hgvs_nt=NC_045512.2:g.963A>G;hgvs_aa=YP_009724390.1:p.Gln321Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03773584905660377;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22530	22530	.	+	.	ID=ID_111;Name=T323I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=324;ao=47;dp=371;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C968T;aa_name=p.T323I;hgvs_nt=NC_045512.2:g.968C>T;hgvs_aa=YP_009724390.1:p.Thr323Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.12668463611859837;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22713	22713	.	+	.	ID=ID_112;Name=P384L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1078;ao=17;dp=1095;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1151T;aa_name=p.P384L;hgvs_nt=NC_045512.2:g.1151C>T;hgvs_aa=YP_009724390.1:p.Pro384Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015525114155251141;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22713	22713	.	+	.	ID=ID_112;Name=P384L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1078;ao=17;dp=1095;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1151T;aa_name=p.P384L;hgvs_nt=NC_045512.2:g.1151C>T;hgvs_aa=YP_009724390.1:p.Pro384Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015525114155251141;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22713	22713	.	+	.	ID=ID_112;Name=P384L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1078;ao=17;dp=1095;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1151T;aa_name=p.P384L;hgvs_nt=NC_045512.2:g.1151C>T;hgvs_aa=YP_009724390.1:p.Pro384Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015525114155251141;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_99;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=Munster et al. (2021);comb_mutation=D80A,D215G,A701V,N501Y,E484K;function_description=Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_100;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,E484K,N501Y,A701V,D614G;function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_114;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=E484K,N501Y;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_115;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation=E484K,N501Y,D614G;function_description=Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	"ID=ID_114;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=Wibmer et al. (2021);comb_mutation=E484K,N501Y;function_description=Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_114;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=E484K,N501Y;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_116;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_114;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=E484K,N501Y;function_description=The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_116;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_117;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_118;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,D614G;function_description=Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_115;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,N501Y,D614G;function_description=~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_115;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation=E484K,N501Y,D614G;function_description=The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_114;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1;citation=Teyssou et al. (2021);comb_mutation=E484K,N501Y;function_description=The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_114;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2;citation=Roquebert et al. (2021);comb_mutation=E484K,N501Y;function_description=B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_119;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=E484K;function_description=Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation. COR-101 lost ~160x binding against this double mutation. Casirivimab lost ~16x binding against this double mutation. Estesevimab lost ~32x binding against this double mutation. Regdanvimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_120;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=N501Y;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_100;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,E484K,N501Y,A701V,D614G;function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_114;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,E484K;function_description=~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_115;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation=E484K,N501Y,D614G;function_description=Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_115;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=E484K,N501Y,D614G;function_description=Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_114;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=E484K,N501Y;function_description=Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_114;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=E484K,N501Y;function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	"ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	"ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_115;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;citation=Pearson et al. (2021);comb_mutation=E484K,N501Y,D614G;function_description=Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_115;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1;citation=Roquebert et al. (2021);comb_mutation=E484K,N501Y,D614G;function_description=36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in le-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_116;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_100;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,E484K,N501Y,A701V,D614G;function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_115;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation=E484K,N501Y,D614G;function_description=In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_114;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,E484K;function_description=In post-vaccination sera from individuals who received one (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_116;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_117;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_118;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,D614G;function_description=This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_115;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,N501Y,D614G;function_description=This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_114;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation=E484K,N501Y;function_description=Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_99;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=D80A,D215G,E484K,N501Y,A701V;function_description=Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_114;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=E484K,N501Y;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_114;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1;citation=Wu et al. (2021);comb_mutation=E484K,N501Y;function_description=In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.1 fold;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_113;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_99;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=Yinda et al. (2021);comb_mutation=D80A,D215G,A701V,N501Y,E484K;function_description=Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_99;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=Staub et al. (2021);comb_mutation=D80A,D215G,A701V,N501Y,E484K;function_description=4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_116;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1096;dp=1096;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22858	22858	.	+	.	ID=ID_121;Name=C432C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1089;ao=7;dp=1096;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1296T;aa_name=p.C432C;hgvs_nt=NC_045512.2:g.1296C>T;hgvs_aa=YP_009724390.1:p.Cys432Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006386861313868613;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_99;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=Munster et al. (2021);comb_mutation=D80A,D215G,K417N,A701V,N501Y;function_description=Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_100;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,K417N,N501Y,A701V,D614G;function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_114;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=K417N,N501Y;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1;citation=Li et al. (2021);comb_mutation=;function_description=Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_115;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation=K417N,N501Y,D614G;function_description=Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_114;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=Wibmer et al. (2021);comb_mutation=K417N,N501Y;function_description=Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_114;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=K417N,N501Y;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=N501Y;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2020);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_124;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_125;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=N501Y;function_description=In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_114;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=K417N,N501Y;function_description=The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_124;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_124;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_125;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_124;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_118;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,D614G;function_description=Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_115;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,N501Y,D614G;function_description=~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_115;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation=K417N,N501Y,D614G;function_description=The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_114;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1;citation=Teyssou et al. (2021);comb_mutation=K417N,N501Y;function_description=The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_114;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2;citation=Roquebert et al. (2021);comb_mutation=K417N,N501Y;function_description=B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_119;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=K417N;function_description=Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation. COR-101 lost ~160x binding against this double mutation. Casirivimab lost ~16x binding against this double mutation. Estesevimab lost ~32x binding against this double mutation. Regdanvimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=N501Y;function_description=Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1;citation=Schmidt et al. (2021);comb_mutation=;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_125;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_100;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,K417N,N501Y,A701V,D614G;function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_114;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_115;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation=K417N,N501Y,D614G;function_description=Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_115;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=K417N,N501Y,D614G;function_description=Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_114;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=K417N,N501Y;function_description=Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_114;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=K417N,N501Y;function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=N501Y;function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.12.28.424451;citation=Andreano et al. (2020);comb_mutation=;function_description=This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_115;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;citation=Pearson et al. (2021);comb_mutation=K417N,N501Y,D614G;function_description=Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_115;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1;citation=Roquebert et al. (2021);comb_mutation=K417N,N501Y,D614G;function_description=36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in le-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_125;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_125;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_100;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,K417N,N501Y,A701V,D614G;function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1084/jem.20202756;citation=Solfrosi et al. (2021);comb_mutation=;function_description=Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.357.78, 95% confidence interval all above twofold difference, one-sample t test).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation=;function_description=E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_115;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation=K417N,N501Y,D614G;function_description=In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S2666-5247(21;citation=Jangra et al. (2021);comb_mutation=;function_description=Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_114;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=In post-vaccination sera from individuals who received one (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_125;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_124;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_118;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,D614G;function_description=This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_115;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,N501Y,D614G;function_description=This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_126;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=D614G,V1176F;function_description=Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_114;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation=K417N,N501Y;function_description=Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_99;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=D80A,D215G,K417N,N501Y,A701V;function_description=Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_114;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=K417N,N501Y;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_114;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1;citation=Wu et al. (2021);comb_mutation=K417N,N501Y;function_description=In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=N501Y;function_description=The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_123;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01270-4;citation=Xie et al. (2021);comb_mutation=N501Y;function_description=In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=http://dx.doi.org/10.1126/science.abd0831;citation=Baum et al. (2020);comb_mutation=;function_description=Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin;citation=Barnes et al. (2020);comb_mutation=;function_description=The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_122;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_99;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=Yinda et al. (2021);comb_mutation=D80A,D215G,K417N,A701V,N501Y;function_description=Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_99;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=Staub et al. (2021);comb_mutation=D80A,D215G,K417N,A701V,N501Y;function_description=4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_125;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1033;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.nejm.org/doi/full/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_99;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=Munster et al. (2021);comb_mutation=D80A,D215G,K417N,A701V,E484K;function_description=Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.mdpi.com/2076-0817/10/2/184/htm;citation=Flores-Alanis et al. (2021);comb_mutation=;function_description=Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_100;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,K417N,E484K,A701V,D614G;function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_114;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=K417N,E484K;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.04.26.441517;citation=Klegerman et al. (2021);comb_mutation=;function_description=Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_115;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation=K417N,E484K,D614G;function_description=Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_114;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=Wibmer et al. (2021);comb_mutation=K417N,E484K;function_description=Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_114;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=K417N,E484K;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=E484K;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation=;function_description=Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_128;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_124;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,D614G;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_128;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=E484K;function_description=In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_114;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=K417N,E484K;function_description=The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_129;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=D614G,Q677H;function_description=Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells for ACE2 affinity changes vs D614G alone, showing a ~70% drop in IC50 (i.e. increased affinity).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1;citation=Santos and Passos (2021);comb_mutation=;function_description=In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1;citation=Liu et al. (2021);comb_mutation=;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2;citation=Zhu et al. (2021);comb_mutation=;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1;citation=Gamez et al. (2021);comb_mutation=;function_description=The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_128;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_124;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,D614G;function_description=~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_128;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_124;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_128;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_117;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,D614G;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_124;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,D614G;function_description=~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_115;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,K417N,D614G;function_description=~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_128;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully];heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_129;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=D614G,Q677H;function_description=Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_115;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation=K417N,E484K,D614G;function_description=The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_114;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1;citation=Teyssou et al. (2021);comb_mutation=K417N,E484K;function_description=The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_114;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2;citation=Roquebert et al. (2021);comb_mutation=K417N,E484K;function_description=B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=E484K;function_description=Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_120;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=K417N;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_100;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,K417N,E484K,A701V,D614G;function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_114;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,E484K;function_description=~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_129;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=D614G,Q677H;function_description=Lentiviral pseudotyped with the key mutations from COH.20G/677H (""Ohio"") lineage was neutralized similarly to D614G in 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_115;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation=K417N,E484K,D614G;function_description=Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_115;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=K417N,E484K,D614G;function_description=Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_114;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=K417N,E484K;function_description=Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_114;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=K417N,E484K;function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=E484K;function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_115;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;citation=Pearson et al. (2021);comb_mutation=K417N,E484K,D614G;function_description=Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_115;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1;citation=Roquebert et al. (2021);comb_mutation=K417N,E484K,D614G;function_description=36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in le-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_128;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_100;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,K417N,E484K,A701V,D614G;function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1;citation=Edara et al. (2021);comb_mutation=;function_description=1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 g (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_115;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation=K417N,E484K,D614G;function_description=In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_114;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,E484K;function_description=In post-vaccination sera from individuals who received one (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_128;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_117;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_124;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_115;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,E484K,D614G;function_description=This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_114;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation=K417N,E484K;function_description=Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation=;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_99;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=D80A,D215G,K417N,E484K,A701V;function_description=Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_114;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=K417N,E484K;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_114;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1;citation=Wu et al. (2021);comb_mutation=K417N,E484K;function_description=In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=E484K;function_description=The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_123;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01270-4;citation=Xie et al. (2021);comb_mutation=E484K;function_description=In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_127;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_99;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=Yinda et al. (2021);comb_mutation=D80A,D215G,K417N,A701V,E484K;function_description=Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_99;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=Staub et al. (2021);comb_mutation=D80A,D215G,K417N,A701V,E484K;function_description=4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_128;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1027;dp=1027;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23311	23311	.	+	.	ID=ID_130;Name=E583D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1089;ao=11;dp=1100;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G1749T;aa_name=p.E583D;hgvs_nt=NC_045512.2:g.1749G>T;hgvs_aa=YP_009724390.1:p.Glu583Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_100;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,K417N,E484K,N501Y,A701V;function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_115;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation=K417N,E484K,N501Y;function_description=Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_112;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=P384L;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_128;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_124;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,N501Y;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_128;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_95;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_102;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D80A;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination showed no change relative to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_105;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D215G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.19x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_116;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=K417N;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_125;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484K;function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_132;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=A701V;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_133;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_93;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_129;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=N501Y,Q677H;function_description=Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells for ACE2 affinity changes vs D614G alone, showing a ~70% drop in IC50 (i.e. increased affinity).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_112;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=P384L;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_128;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_124;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,N501Y;function_description=~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_112;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=P384L;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_128;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_124;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_128;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_125;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_116;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_117;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,N501Y;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_124;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,N501Y;function_description=~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_118;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,K417N;function_description=Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_115;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,K417N,N501Y;function_description=~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_128;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_129;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=N501Y,Q677H;function_description=Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_115;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation=K417N,E484K,N501Y;function_description=The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oralnasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_125;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=E484K;function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_100;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,K417N,E484K,N501Y,A701V;function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_129;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=N501Y,Q677H;function_description=Lentiviral pseudotyped with the key mutations from COH.20G/677H (""Ohio"") lineage was neutralized similarly to D614G in 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_115;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation=K417N,E484K,N501Y;function_description=Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_115;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=K417N,E484K,N501Y;function_description=Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_115;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;citation=Pearson et al. (2021);comb_mutation=K417N,E484K,N501Y;function_description=Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_115;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1;citation=Roquebert et al. (2021);comb_mutation=K417N,E484K,N501Y;function_description=36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in le-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_128;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_95;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F;function_description=1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_102;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D80A;function_description=2.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_105;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D215G;function_description=2.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_116;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=K417N;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_125;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484K;function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_132;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_133;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_93;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_125;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=E484K;function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_100;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,K417N,E484K,N501Y,A701V;function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_115;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation=K417N,E484K,N501Y;function_description=In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_128;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_125;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_116;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_117;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,N501Y;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_124;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,N501Y;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_118;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,E484K;function_description=This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_115;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,E484K,N501Y;function_description=This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (911 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccinationmean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_126;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=E484K,V1176F;function_description=Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_107;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=humoral response durability;source=https://dx.doi.org/10.3390%2Fv13040661;citation=Brehm et al. (2021);comb_mutation=A222V;function_description=27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3), i.e. with a  9 month interval. Both cases were mild. No significant differences in the neutralizing capacity of the two linages were observed in 4 sera taken (1 pre-reinfection,  three post-reinfection). Neutralizing antibody titres (IC50) before and immediately after re-infection were <300 against  both strains, and jumped >7x upon re-infection. Viral titres were also higher in the second case. Second case also includes N:p.A220V;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_131;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_107;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://dx.doi.org/10.3390%2Fv13040661;citation=Brehm et al. (2021);comb_mutation=A222V;function_description=27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3). Both cases were mild. Second case also includes N:p.A220V;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_128;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_95;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L18F;function_description=1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_102;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D80A;function_description=1.64x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.35x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_105;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D215G;function_description=1.79x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_116;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=K417N;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_125;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484K;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_132;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_133;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_93;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1104;dp=1104;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_134;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1099;ao=7;dp=1106;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006329113924050633;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_133;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1099;ao=7;dp=1106;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006329113924050633;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_134;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1099;ao=7;dp=1106;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006329113924050633;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=;function_description=Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_133;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1099;ao=7;dp=1106;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006329113924050633;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_134;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1099;ao=7;dp=1106;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006329113924050633;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_133;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1099;ao=7;dp=1106;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006329113924050633;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23593	23593	.	+	.	ID=ID_129;Name=Q677H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1130;ao=8;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=C;nt_name=g.G2031C;aa_name=p.Q677H;hgvs_nt=NC_045512.2:g.2031G>C;hgvs_aa=YP_009724390.1:p.Gln677His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006993006993006993;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=N501Y,D614G;function_description=Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells for ACE2 affinity changes vs D614G alone, showing a ~70% drop in IC50 (i.e. increased affinity).;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23593	23593	.	+	.	ID=ID_129;Name=Q677H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1130;ao=8;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=C;nt_name=g.G2031C;aa_name=p.Q677H;hgvs_nt=NC_045512.2:g.2031G>C;hgvs_aa=YP_009724390.1:p.Gln677His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006993006993006993;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=N501Y,D614G;function_description=Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23593	23593	.	+	.	"ID=ID_129;Name=Q677H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1130;ao=8;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=C;nt_name=g.G2031C;aa_name=p.Q677H;hgvs_nt=NC_045512.2:g.2031G>C;hgvs_aa=YP_009724390.1:p.Gln677His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006993006993006993;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=N501Y,D614G;function_description=Lentiviral pseudotyped with the key mutations from COH.20G/677H (""Ohio"") lineage was neutralized similarly to D614G in 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23593	23593	.	+	.	ID=ID_129;Name=Q677H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1130;ao=6;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G2031T;aa_name=p.Q677H;hgvs_nt=NC_045512.2:g.2031G>T;hgvs_aa=YP_009724390.1:p.Gln677His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005244755244755245;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=N501Y,D614G;function_description=Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells for ACE2 affinity changes vs D614G alone, showing a ~70% drop in IC50 (i.e. increased affinity).;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23593	23593	.	+	.	ID=ID_129;Name=Q677H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1130;ao=6;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G2031T;aa_name=p.Q677H;hgvs_nt=NC_045512.2:g.2031G>T;hgvs_aa=YP_009724390.1:p.Gln677His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005244755244755245;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=N501Y,D614G;function_description=Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23593	23593	.	+	.	"ID=ID_129;Name=Q677H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1130;ao=6;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G2031T;aa_name=p.Q677H;hgvs_nt=NC_045512.2:g.2031G>T;hgvs_aa=YP_009724390.1:p.Gln677His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005244755244755245;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=N501Y,D614G;function_description=Lentiviral pseudotyped with the key mutations from COH.20G/677H (""Ohio"") lineage was neutralized similarly to D614G in 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23611	23611	.	+	.	ID=ID_135;Name=R683R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1113;ao=24;dp=1137;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G2049T;aa_name=p.R683R;hgvs_nt=NC_045512.2:g.2049G>T;hgvs_aa=YP_009724390.1:p.Arg683Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021108179419525065;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_99;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1140;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=Munster et al. (2021);comb_mutation=D80A,D215G,K417N,N501Y,E484K;function_description=Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_100;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1140;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,K417N,E484K,N501Y,D614G;function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_132;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1140;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_136;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1140;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_100;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1140;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,K417N,E484K,N501Y,D614G;function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_132;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1140;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_100;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1140;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation=D80A,D215G,K417N,E484K,N501Y,D614G;function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_99;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1140;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=D80A,D215G,K417N,E484K,N501Y;function_description=Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_136;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1140;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.33 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_99;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1140;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=Yinda et al. (2021);comb_mutation=D80A,D215G,K417N,N501Y,E484K;function_description=Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_99;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1140;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=Staub et al. (2021);comb_mutation=D80A,D215G,K417N,N501Y,E484K;function_description=4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_132;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1140;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23758	23758	.	+	.	ID=ID_137;Name=T732T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1114;ao=26;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C2196T;aa_name=p.T732T;hgvs_nt=NC_045512.2:g.2196C>T;hgvs_aa=YP_009724390.1:p.Thr732Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02280701754385965;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23764	23764	.	+	.	ID=ID_138;Name=T734T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1058;ao=82;dp=1140;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A2202T;aa_name=p.T734T;hgvs_nt=NC_045512.2:g.2202A>T;hgvs_aa=YP_009724390.1:p.Thr734Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07192982456140351;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24087	24087	.	+	.	ID=ID_139;Name=G842D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1122;ao=18;dp=1140;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G2525A;aa_name=p.G842D;hgvs_nt=NC_045512.2:g.2525G>A;hgvs_aa=YP_009724390.1:p.Gly842Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015789473684210527;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24125	24125	.	+	.	ID=ID_140;Name=F855L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1120;ao=20;dp=1140;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T2563C;aa_name=p.F855L;hgvs_nt=NC_045512.2:g.2563T>C;hgvs_aa=YP_009724390.1:p.Phe855Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.017543859649122806;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24415	24415	.	+	.	ID=ID_141;Name=V951V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1128;ao=12;dp=1140;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G2853A;aa_name=p.V951V;hgvs_nt=NC_045512.2:g.2853G>A;hgvs_aa=YP_009724390.1:p.Val951Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010526315789473684;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24755	24755	.	+	.	ID=ID_142;Name=V1065L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1133;ao=9;dp=1142;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G3193T;aa_name=p.V1065L;hgvs_nt=NC_045512.2:g.3193G>T;hgvs_aa=YP_009724390.1:p.Val1065Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00788091068301226;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24794	24794	.	+	.	ID=ID_143;Name=A1078S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1133;ao=9;dp=1142;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G3232T;aa_name=p.A1078S;hgvs_nt=NC_045512.2:g.3232G>T;hgvs_aa=YP_009724390.1:p.Ala1078Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00788091068301226;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25088	25088	.	+	.	ID=ID_126;Name=V1176F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1115;ao=26;dp=1141;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G3526T;aa_name=p.V1176F;hgvs_nt=NC_045512.2:g.3526G>T;hgvs_aa=YP_009724390.1:p.Val1176Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022787028921998246;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=E484K,D614G;function_description=Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25297	25297	.	+	.	ID=ID_144;Name=K1245N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1121;ao=20;dp=1141;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G3735T;aa_name=p.K1245N;hgvs_nt=NC_045512.2:g.3735G>T;hgvs_aa=YP_009724390.1:p.Lys1245Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.017528483786152498;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25563	25563	.	+	.	ID=ID_145;Name=Q57H;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1142;dp=1142;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G171T;aa_name=p.Q57H;hgvs_nt=NC_045512.2:g.171G>T;hgvs_aa=YP_009724391.1:p.Gln57His;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25603	25603	.	+	.	ID=ID_146;Name=L71L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1134;ao=9;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C211T;aa_name=p.L71L;hgvs_nt=NC_045512.2:g.211C>T;hgvs_aa=YP_009724391.1:p.Leu71Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007874015748031496;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25614	25614	.	+	.	ID=ID_147;Name=S74S;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=819;ao=324;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C222T;aa_name=p.S74S;hgvs_nt=NC_045512.2:g.222C>T;hgvs_aa=YP_009724391.1:p.Ser74Ser;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.28346456692913385;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25784	25784	.	+	.	ID=ID_148;Name=W131L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=574;ao=538;dp=1112;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G392T;aa_name=p.W131L;hgvs_nt=NC_045512.2:g.392G>T;hgvs_aa=YP_009724391.1:p.Trp131Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.48381294964028776;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25844	25844	.	+	.	ID=ID_149;Name=T151I;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1104;ao=9;dp=1113;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C452T;aa_name=p.T151I;hgvs_nt=NC_045512.2:g.452C>T;hgvs_aa=YP_009724391.1:p.Thr151Ile;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008086253369272238;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25904	25904	.	+	.	ID=ID_150;Name=S171L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1101;dp=1101;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C512T;aa_name=p.S171L;hgvs_nt=NC_045512.2:g.512C>T;hgvs_aa=YP_009724391.1:p.Ser171Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26152	26152	.	+	.	ID=ID_151;Name=G254X;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=576;ao=568;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G760T;aa_name=p.G254X;hgvs_nt=NC_045512.2:g.760G>T;hgvs_aa=YP_009724391.1:p.Gly254Xaa;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=NONSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4965034965034965;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26256	26256	.	+	.	ID=ID_152;Name=F4F;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1129;ao=15;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C12T;aa_name=p.F4F;hgvs_nt=NC_045512.2:g.12C>T;hgvs_aa=YP_009724392.1:p.Phe4Phe;hgvs_alias=n/a;vcf_gene=E;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013111888111888112;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26446	26446	.	+	.	ID=ID_153;Name=S68P;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1127;ao=14;dp=1141;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T202C;aa_name=p.S68P;hgvs_nt=NC_045512.2:g.202T>C;hgvs_aa=YP_009724392.1:p.Ser68Pro;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012269938650306749;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26456	26456	.	+	.	ID=ID_154;Name=P71L;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1141;dp=1141;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C212T;aa_name=p.P71L;hgvs_nt=NC_045512.2:g.212C>T;hgvs_aa=YP_009724392.1:p.Pro71Leu;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26520	26520	.	+	.	ID=ID_155;Name=g.G-3C;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1131;ao=10;dp=1141;sample_size=1180;Reference_seq=G;Variant_seq=C;nt_name=g.G-3C;aa_name=;hgvs_nt=NC_045512.2:g.3G>C;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=M;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008764241893076249;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26645	26645	.	+	.	ID=ID_156;Name=N41N;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1088;ao=56;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C123T;aa_name=p.N41N;hgvs_nt=NC_045512.2:g.123C>T;hgvs_aa=YP_009724393.1:p.Asn41Asn;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04895104895104895;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26735	26735	.	+	.	ID=ID_157;Name=Y71Y;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1128;ao=16;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C213T;aa_name=p.Y71Y;hgvs_nt=NC_045512.2:g.213C>T;hgvs_aa=YP_009724393.1:p.Tyr71Tyr;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013986013986013986;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26894	26894	.	+	.	ID=ID_158;Name=L124L;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1128;ao=16;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C372T;aa_name=p.L124L;hgvs_nt=NC_045512.2:g.372C>T;hgvs_aa=YP_009724393.1:p.Leu124Leu;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013986013986013986;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27145	27145	.	+	.	ID=ID_159;Name=T208I;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1115;ao=29;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C623T;aa_name=p.T208I;hgvs_nt=NC_045512.2:g.623C>T;hgvs_aa=YP_009724393.1:p.Thr208Ile;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025349650349650348;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27193	27193	.	+	.	ID=ID_160;Name=g.T-9C;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1124;ao=20;dp=1144;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T-9C;aa_name=;hgvs_nt=NC_045512.2:g.9T>C;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.017482517482517484;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27476	27476	.	+	.	ID=ID_161;Name=T28I;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1138;ao=6;dp=1144;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C83T;aa_name=p.T28I;hgvs_nt=NC_045512.2:g.83C>T;hgvs_aa=YP_009724395.1:p.Thr28Ile;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005244755244755245;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27643	27643	.	+	.	ID=ID_162;Name=P84S;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1120;ao=16;dp=1136;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C250T;aa_name=p.P84S;hgvs_nt=NC_045512.2:g.250C>T;hgvs_aa=YP_009724395.1:p.Pro84Ser;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014084507042253521;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27659	27659	.	+	.	ID=ID_163;Name=R89I;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1129;ao=7;dp=1136;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G266T;aa_name=p.R89I;hgvs_nt=NC_045512.2:g.266G>T;hgvs_aa=YP_009724395.1:p.Arg89Ile;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006161971830985915;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	complex	27697	27697	.	+	.	ID=ID_164;Name=L102_I103delinsF;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1107;ao=29;dp=1138;sample_size=1180;Reference_seq=CTTA;Variant_seq=T;nt_name=g.CTTA304_307T;aa_name=p.L102_I103delinsF;hgvs_nt=n/a;hgvs_aa=YP_009724395.1:p.Leu102_Ile103delinsPhe;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025483304042179262;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27870	27870	.	+	.	ID=ID_165;Name=E39X;alias=n/a;gene=ORF7b;protein_name=ORF7b;protein_symbol=ORF7b;protein_id=YP_009725318.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=900;ao=133;dp=1033;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G115T;aa_name=p.E39X;hgvs_nt=NC_045512.2:g.115G>T;hgvs_aa=YP_009725318.1:p.Glu39Xaa;hgvs_alias=n/a;vcf_gene=ORF7b;mutation_type=NONSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1287512100677638;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27923	27923	.	+	.	ID=ID_166;Name=I10I;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=994;ao=40;dp=1034;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C30T;aa_name=p.I10I;hgvs_nt=NC_045512.2:g.30C>T;hgvs_aa=YP_009724396.1:p.Ile10Ile;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03868471953578337;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27998	27998	.	+	.	ID=ID_167;Name=D35D;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1003;ao=26;dp=1029;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C105T;aa_name=p.D35D;hgvs_nt=NC_045512.2:g.105C>T;hgvs_aa=YP_009724396.1:p.Asp35Asp;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025267249757045675;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28156	28156	.	+	.	ID=ID_168;Name=I88N;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1003;ao=7;dp=1010;sample_size=1180;Reference_seq=T;Variant_seq=A;nt_name=g.T263A;aa_name=p.I88N;hgvs_nt=NC_045512.2:g.263T>A;hgvs_aa=YP_009724396.1:p.Ile88Asn;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006930693069306931;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28164	28164	.	+	.	ID=ID_169;Name=Q91X;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1003;ao=30;dp=1033;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C271T;aa_name=p.Q91X;hgvs_nt=NC_045512.2:g.271C>T;hgvs_aa=YP_009724396.1:p.Gln91Xaa;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=NONSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02904162633107454;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	complex	28251	28251	.	+	.	ID=ID_170;Name=FI120VL;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=27;dp=1023;sample_size=1180;Reference_seq=TTCA;Variant_seq=GTTC;nt_name=g.TTCA358_361GTTC;aa_name=p.FI120VL;hgvs_nt=n/a;hgvs_aa=YP_009724396.1:p.PheIle120ValLeu;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.026392961876832845;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	mnp	28251	28251	.	+	.	ID=ID_171;Name=I121L;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=105;dp=1023;sample_size=1180;Reference_seq=TTCA;Variant_seq=TTTC;nt_name=g.CA360_361TC;aa_name=p.I121L;hgvs_nt=n/a;hgvs_aa=YP_009724396.1:p.Ile121Leu;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10263929618768329;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28251	28251	.	+	.	ID=ID_172;Name=F120F;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=890;dp=1023;sample_size=1180;Reference_seq=TTCA;Variant_seq=TTTA;nt_name=g.C360T;aa_name=p.F120F;hgvs_nt=NC_045512.2:g.360C>T;hgvs_aa=YP_009724396.1:p.Phe120Phe;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8699902248289345;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28310	28310	.	+	.	ID=ID_173;Name=P13S;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1008;ao=28;dp=1036;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C37T;aa_name=p.P13S;hgvs_nt=NC_045512.2:g.37C>T;hgvs_aa=YP_009724397.2:p.Pro13Ser;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1;citation=de Silva et al. (2021);comb_mutation=;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28311	28311	.	+	.	ID=ID_174;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=978;ao=58;dp=1036;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.055984555984555984;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1;citation=de Silva et al. (2021);comb_mutation=;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28311	28311	.	+	.	ID=ID_174;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=978;ao=58;dp=1036;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.055984555984555984;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28642	28642	.	+	.	ID=ID_175;Name=Y123Y;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1066;ao=78;dp=1144;sample_size=1180;Reference_seq=T;Variant_seq=C;nt_name=g.T369C;aa_name=p.Y123Y;hgvs_nt=NC_045512.2:g.369T>C;hgvs_aa=YP_009724397.2:p.Tyr123Tyr;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06818181818181818;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28739	28739	.	+	.	ID=ID_176;Name=A156S;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1122;ao=22;dp=1144;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G466T;aa_name=p.A156S;hgvs_nt=NC_045512.2:g.466G>T;hgvs_aa=YP_009724397.2:p.Ala156Ser;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.019230769230769232;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28795	28795	.	+	.	ID=ID_177;Name=E174E;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1137;ao=7;dp=1144;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A522G;aa_name=p.E174E;hgvs_nt=NC_045512.2:g.522A>G;hgvs_aa=YP_009724397.2:p.Glu174Glu;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006118881118881119;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28882	28882	.	+	.	ID=ID_178;Name=R203R;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1136;ao=7;dp=1143;sample_size=1180;Reference_seq=G;Variant_seq=A;nt_name=g.G609A;aa_name=p.R203R;hgvs_nt=NC_045512.2:g.609G>A;hgvs_aa=YP_009724397.2:p.Arg203Arg;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006124234470691163;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28887	28887	.	+	.	ID=ID_179;Name=T205I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1143;dp=1143;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C614T;aa_name=p.T205I;hgvs_nt=NC_045512.2:g.614C>T;hgvs_aa=YP_009724397.2:p.Thr205Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29027	29027	.	+	.	ID=ID_180;Name=A252S;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1123;ao=17;dp=1140;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G754T;aa_name=p.A252S;hgvs_nt=NC_045512.2:g.754G>T;hgvs_aa=YP_009724397.2:p.Ala252Ser;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014912280701754385;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29053	29053	.	+	.	ID=ID_181;Name=Q260H;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1113;ao=10;dp=1123;sample_size=1180;Reference_seq=A;Variant_seq=C;nt_name=g.A780C;aa_name=p.Q260H;hgvs_nt=NC_045512.2:g.780A>C;hgvs_aa=YP_009724397.2:p.Gln260His;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008904719501335707;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29200	29200	.	+	.	ID=ID_182;Name=P309P;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1113;ao=9;dp=1122;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C927T;aa_name=p.P309P;hgvs_nt=NC_045512.2:g.927C>T;hgvs_aa=YP_009724397.2:p.Pro309Pro;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008021390374331552;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29254	29254	.	+	.	ID=ID_183;Name=S327S;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1095;ao=29;dp=1124;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G981T;aa_name=p.S327S;hgvs_nt=NC_045512.2:g.981G>T;hgvs_aa=YP_009724397.2:p.Ser327Ser;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025800711743772242;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29358	29358	.	+	.	"ID=ID_184;Name=T362I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1002;ao=138;dp=1140;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1085T;aa_name=p.T362I;hgvs_nt=NC_045512.2:g.1085C>T;hgvs_aa=YP_009724397.2:p.Thr362Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.12105263157894737;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1;citation=de Silva et al. (2021);comb_mutation=;function_description=Variant causes complete loss of T cell line responsiveness to A*03:01/A*11:01-restricted CD8+ N epitope  KTFPPTEPK 361-369(2,8,10,20), which otherwise is ""consistently dominant and of high magnitude"".;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	29406	29406	.	+	.	ID=ID_185;Name=E378V;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1133;ao=7;dp=1140;sample_size=1180;Reference_seq=A;Variant_seq=T;nt_name=g.A1133T;aa_name=p.E378V;hgvs_nt=NC_045512.2:g.1133A>T;hgvs_aa=YP_009724397.2:p.Glu378Val;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0061403508771929825;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29518	29518	.	+	.	ID=ID_186;Name=D415D;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1132;ao=9;dp=1141;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C1245T;aa_name=p.D415D;hgvs_nt=NC_045512.2:g.1245C>T;hgvs_aa=YP_009724397.2:p.Asp415Asp;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007887817703768623;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29700	29700	.	+	.	ID=ID_187;Name=g.A29700G;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1092;ao=49;dp=1141;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A29700G;aa_name=;hgvs_nt=NC_045512.2:g.29700A>G;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04294478527607362;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29706	29706	.	+	.	ID=ID_188;Name=g.G29706T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1124;ao=17;dp=1141;sample_size=1180;Reference_seq=G;Variant_seq=T;nt_name=g.G29706T;aa_name=;hgvs_nt=NC_045512.2:g.29706G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014899211218229623;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29731	29731	.	+	.	ID=ID_189;Name=g.A29731G;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1126;ao=13;dp=1139;sample_size=1180;Reference_seq=A;Variant_seq=G;nt_name=g.A29731G;aa_name=;hgvs_nt=NC_045512.2:g.29731A>G;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01141352063213345;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29754	29754	.	+	.	ID=ID_190;Name=g.C29754T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=822;ao=287;dp=1109;sample_size=1180;Reference_seq=C;Variant_seq=T;nt_name=g.C29754T;aa_name=;hgvs_nt=NC_045512.2:g.29754C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.2587917042380523;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Beta;variant_type=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;status=de_escalated;
